Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDRAE VANDROSS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1205079373
CMS profile
2789901
Location
AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,083.01

10 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $935.64 5
Food and Beverage $147.37 5

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $935.64 5
Tempus AI, Inc $49.84 2
Deciphera Pharmaceuticals Inc. $41.25 1
JAZZ PHARMACEUTICALS INC. $33.77 1
Novartis Pharmaceuticals Corporation $22.51 1

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDRAE VANDROSS

NPI 1205079373 · CMS profile ID 2789901

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205079373?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDRAE VANDROSS, NPI 1205079373, CMS profile ID 2789901. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205079373?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ANDRAE VANDROSS, NPI 1205079373, CMS profile ID 2789901. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205079373?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ANDRAE VANDROSS, NPI 1205079373, CMS profile ID 2789901, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1205079373?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

10 matching records · $1,083.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 10 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–10 of 10.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $57.1312/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106269842 CMS
JAZZ PHARMACEUTICALS INC. $33.7712/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150204062 CMS
ABBVIE INC. $523.4308/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106269838 CMS
ABBVIE INC. $82.2008/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106269840 CMS
ABBVIE INC. $183.6608/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106269834 CMS
ABBVIE INC. $89.2208/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106269836 CMS
Tempus AI, Inc $28.7306/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150176366 CMS
Deciphera Pharmaceuticals Inc. $41.2506/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145875799 CMS
Novartis Pharmaceuticals Corporation $22.5105/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087436420 CMS
Tempus AI, Inc $21.1103/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150176364 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $175.94 3
PY2020 $44.69 3
PY2021 $107.19 6
PY2022 $430.20 11
PY2023 $385.16 4
PY2024 $1,083.01 10
PY2025 $3,168.19 7

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $874,433.33 238
PY2024 Principal investigator $413,921.09 482
PY2023 Principal investigator $420,700.05 715
PY2022 Principal investigator $499,990.99 172
PY2021 Principal investigator $187,276.47 47

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

482 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,200.00 12/31/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS
A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with ABBV-514 as a Single Agent and in Combination with Budigalimab No dispute reported 06/30/2026 1100766455
Principal investigator 1 ABBVIE INC. $75.00 12/24/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100762470
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,875.00 12/20/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1146136947
Principal investigator 1 Servier BioInnovation $60.75 12/18/2024 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1153019909
Principal investigator 1 Deciphera Pharmaceuticals Inc. $825.00 11/30/2024 Non-covered Recipient Entity
NEXT ONCOLOGY - AUSTIN
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1146136771
Principal investigator 1 ABBVIE INC. $75.00 11/27/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100756649
Principal investigator 1 Deciphera Pharmaceuticals Inc. $239.00 11/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1146136723
Principal investigator 1 Exelixis Inc. $1,644.30 11/04/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1138629822
Principal investigator 1 Exelixis Inc. $3,000.00 11/04/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1138629824
Principal investigator 1 Exelixis Inc. $24,750.00 11/04/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1138629834
Principal investigator 1 Exelixis Inc. $10,000.00 11/04/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1138629892
Principal investigator 1 Exelixis Inc. $5,000.00 11/04/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1138629900
Principal investigator 1 Servier BioInnovation $1,914.00 11/04/2024 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1153019911
Principal investigator 1 Servier BioInnovation $5,000.00 11/04/2024 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1153019913
Principal investigator 1 Servier BioInnovation $24,750.00 11/04/2024 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1153019915
Principal investigator 1 Exelixis Inc. $3,104.00 10/31/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629910
Principal investigator 1 Exelixis Inc. $24,750.00 10/31/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629912
Principal investigator 1 ABBVIE INC. $1,155.60 10/21/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100749472
Principal investigator 1 ABBVIE INC. $2,511.00 10/21/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100749474
Principal investigator 1 ABBVIE INC. $1,898.10 10/21/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100749476
Principal investigator 1 ABBVIE INC. $4,313.25 10/21/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100749478
Principal investigator 1 ABBVIE INC. $8,925.00 10/21/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100749482
Principal investigator 1 ABBVIE INC. $4,023.00 10/21/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100749484
Principal investigator 1 ABBVIE INC. $5,383.80 10/21/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100749486
Principal investigator 1 ABBVIE INC. $5,782.05 10/21/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100749488
Principal investigator 1 ABBVIE INC. $1,601.10 10/21/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100749490
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,115.00 07/22/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1146135927
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 07/22/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1146135929
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,589.00 07/22/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1146135931
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,801.00 07/22/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1146135933
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,009.00 07/22/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1146135935
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,006.00 07/22/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1146135937
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 07/22/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1146135939
Principal investigator 1 Exelixis Inc. $235.00 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629604
Principal investigator 1 Exelixis Inc. $500.00 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629606
Principal investigator 1 Exelixis Inc. $500.00 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629610
Principal investigator 1 Exelixis Inc. $50.00 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629622
Principal investigator 1 Exelixis Inc. $250.00 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629624
Principal investigator 1 Exelixis Inc. $450.00 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629656
Principal investigator 1 Exelixis Inc. $500.00 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629658
Principal investigator 1 Exelixis Inc. $275.00 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629664
Principal investigator 1 Exelixis Inc. $97.20 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629666
Principal investigator 1 Exelixis Inc. $399.74 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629676
Principal investigator 1 Exelixis Inc. $58.05 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629678
Principal investigator 1 Exelixis Inc. $275.00 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629684
Principal investigator 1 Exelixis Inc. $67.50 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629686
Principal investigator 1 Exelixis Inc. $59.40 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629696
Principal investigator 1 Exelixis Inc. $450.00 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629710
Principal investigator 1 Exelixis Inc. $275.00 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629728
Principal investigator 1 Exelixis Inc. $99.90 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629758
Principal investigator 1 Exelixis Inc. $27.00 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629766
Principal investigator 1 Exelixis Inc. $51.30 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629768
Principal investigator 1 Exelixis Inc. $500.00 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629770
Principal investigator 1 Exelixis Inc. $225.00 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629772
Principal investigator 1 Exelixis Inc. $129.60 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629774
Principal investigator 1 Exelixis Inc. $275.00 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629780
Principal investigator 1 Exelixis Inc. $365.00 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629784
Principal investigator 1 Exelixis Inc. $85.05 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629790
Principal investigator 1 Exelixis Inc. $500.00 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629796
Principal investigator 1 Exelixis Inc. $49.95 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629798
Principal investigator 1 Exelixis Inc. $482.63 07/15/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629802
Principal investigator 1 Exelixis Inc. $129.60 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629608
Principal investigator 1 Exelixis Inc. $27.00 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629612
Principal investigator 1 Exelixis Inc. $49.95 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629614
Principal investigator 1 Exelixis Inc. $67.50 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629616
Principal investigator 1 Exelixis Inc. $67.50 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629618
Principal investigator 1 Exelixis Inc. $85.05 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629620
Principal investigator 1 Exelixis Inc. $450.00 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629628
Principal investigator 1 Exelixis Inc. $85.05 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629630
Principal investigator 1 Exelixis Inc. $59.40 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629632
Principal investigator 1 Exelixis Inc. $49.95 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629638
Principal investigator 1 Exelixis Inc. $97.20 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629642
Principal investigator 1 Exelixis Inc. $1,175.85 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629644
Principal investigator 1 Exelixis Inc. $27.00 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629650
Principal investigator 1 Exelixis Inc. $97.20 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629652
Principal investigator 1 Exelixis Inc. $59.40 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629654
Principal investigator 1 Exelixis Inc. $235.00 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629660
Principal investigator 1 Exelixis Inc. $235.00 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629662
Principal investigator 1 Exelixis Inc. $58.05 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629668
Principal investigator 1 Exelixis Inc. $97.20 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629670
Principal investigator 1 Exelixis Inc. $59.40 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629672
Principal investigator 1 Exelixis Inc. $97.20 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629680
Principal investigator 1 Exelixis Inc. $85.05 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629688
Principal investigator 1 Exelixis Inc. $450.00 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629690
Principal investigator 1 Exelixis Inc. $58.05 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629692
Principal investigator 1 Exelixis Inc. $99.90 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629698
Principal investigator 1 Exelixis Inc. $1,250.00 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629704
Principal investigator 1 Exelixis Inc. $99.90 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629708
Principal investigator 1 Exelixis Inc. $51.30 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629712
Principal investigator 1 Exelixis Inc. $85.05 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629716
Principal investigator 1 Exelixis Inc. $51.30 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629720
Principal investigator 1 Exelixis Inc. $67.50 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629722
Principal investigator 1 Exelixis Inc. $49.95 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629724
Principal investigator 1 Exelixis Inc. $450.00 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629726
Principal investigator 1 Exelixis Inc. $85.05 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629730
Principal investigator 1 Exelixis Inc. $49.95 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629732
Principal investigator 1 Exelixis Inc. $27.00 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629734
Principal investigator 1 Exelixis Inc. $99.90 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629736
Principal investigator 1 Exelixis Inc. $133.65 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629738
Principal investigator 1 Exelixis Inc. $59.40 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629742
Principal investigator 1 Exelixis Inc. $27.00 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629744
Principal investigator 1 Exelixis Inc. $235.00 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629746
Principal investigator 1 Exelixis Inc. $235.00 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629748
Principal investigator 1 Exelixis Inc. $51.30 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629750
Principal investigator 1 Exelixis Inc. $58.05 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629752
Principal investigator 1 Exelixis Inc. $85.05 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629754
Principal investigator 1 Exelixis Inc. $450.00 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629756
Principal investigator 1 Exelixis Inc. $450.00 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629762
Principal investigator 1 Exelixis Inc. $99.90 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629778
Principal investigator 1 Exelixis Inc. $51.30 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629788
Principal investigator 1 Exelixis Inc. $58.05 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629792
Principal investigator 1 Exelixis Inc. $67.50 07/01/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629800
Principal investigator 1 ABBVIE INC. $685.00 06/26/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100724500
Principal investigator 1 ABBVIE INC. $1,315.00 06/26/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100724502
Principal investigator 1 ABBVIE INC. $485.00 06/26/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100724504
Principal investigator 1 Deciphera Pharmaceuticals Inc. $25,240.00 06/26/2024 Non-covered Recipient Entity
NEXT ONCOLOGY - AUSTIN
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1146135803
Principal investigator 1 Exelixis Inc. $1,175.85 06/03/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628918
Principal investigator 1 Exelixis Inc. $1,310.85 06/03/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628920
Principal investigator 1 Exelixis Inc. $4,105.35 06/03/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628932
Principal investigator 1 Exelixis Inc. $1,175.85 06/03/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629288
Principal investigator 1 Exelixis Inc. $1,175.85 06/03/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629302
Principal investigator 1 Exelixis Inc. $1,290.60 06/03/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629326
Principal investigator 1 Exelixis Inc. $3,871.80 06/03/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629502
Principal investigator 1 Exelixis Inc. $4,361.85 06/03/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629602
Principal investigator 1 ABBVIE INC. $2,143.80 05/20/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100719086
Principal investigator 1 ABBVIE INC. $2,590.65 05/20/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100719098
Principal investigator 1 Deciphera Pharmaceuticals Inc. $25,240.00 05/15/2024 Non-covered Recipient Entity
NEXT ONCOLOGY - AUSTIN
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1146135505
Principal investigator 1 ABBVIE INC. $150.00 04/29/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100715300
Principal investigator 1 AstraZeneca UK Limited $235.00 04/26/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
A Phase I Open-label Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) Rifampicin (a CYP3A4 Inducer) and Omeprazole (a Proton Pump Inhibitor) on the Pharmacokinetics of a Single Oral Dose of Adavosertib in Patients with Advanced Solid Tumours No dispute reported 06/30/2026 1110841582
Principal investigator 1 Merck Sharp & Dohme LLC $14,200.00 04/25/2024 Non-covered Recipient Entity
NEXT Austin
A Phase 1,1b Dose Escalation,Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1136441754
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628912
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628914
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628916
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628922
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628924
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628926
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628928
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628930
Principal investigator 1 Exelixis Inc. $275.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628934
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628936
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628938
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628940
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628942
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628944
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628946
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628948
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628950
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628952
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628954
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628956
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628958
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628960
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628962
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628964
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628966
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628968
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628970
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628972
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628974
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628976
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628978
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628980
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628982
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628984
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628988
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628990
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628992
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628994
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628996
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628998
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629000
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629002
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629004
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629006
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629008
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629010
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629012
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629014
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629016
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629018
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629020
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629022
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629024
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629026
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629028
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629030
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629032
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629034
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629036
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629038
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629040
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629042
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629044
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629046
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629048
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629050
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629052
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629054
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629056
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629058
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629060
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629062
Principal investigator 1 Exelixis Inc. $500.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629064
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629066
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629068
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629070
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629072
Principal investigator 1 Exelixis Inc. $122.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629074
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629076
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629078
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629080
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629082
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629084
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629086
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629088
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629090
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629092
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629094
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629096
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629098
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629100
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629104
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629106
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629108
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629110
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629112
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629114
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629116
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629118
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629120
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629122
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629124
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629126
Principal investigator 1 Exelixis Inc. $500.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629128
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629130
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629132
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629134
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629136
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629138
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629140
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629142
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629144
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629146
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629148
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629150
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629152
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629154
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629156
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629158
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629160
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629162
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629166
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629168
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629170
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629172
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629174
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629176
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629178
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629180
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629182
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629184
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629186
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629188
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629190
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629192
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629194
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629196
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629198
Principal investigator 1 Exelixis Inc. $150.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629200
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629202
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629206
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629208
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629210
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629212
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629214
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629216
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629218
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629220
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629222
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629224
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629226
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629228
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629230
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629232
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629234
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629236
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629238
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629240
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629242
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629244
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629246
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629248
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629250
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629252
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629254
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629256
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629258
Principal investigator 1 Exelixis Inc. $50.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629260
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629262
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629264
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629266
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629268
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629270
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629272
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629274
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629276
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629278
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629280
Principal investigator 1 Exelixis Inc. $142.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629282
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629284
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629286
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629290
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629292
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629294
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629296
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629300
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629306
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629308
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629310
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629312
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629314
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629316
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629318
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629322
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629324
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629328
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629330
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629332
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629334
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629336
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629338
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629340
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629342
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629344
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629346
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629348
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629350
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629352
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629354
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629356
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629358
Principal investigator 1 Exelixis Inc. $500.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629360
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629362
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629364
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629366
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629368
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629370
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629372
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629374
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629376
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629378
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629380
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629382
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629384
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629386
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629388
Principal investigator 1 Exelixis Inc. $450.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629390
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629392
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629394
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629396
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629398
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629400
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629402
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629404
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629406
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629408
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629410
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629412
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629414
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629416
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629418
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629420
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629422
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629424
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629426
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629428
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629430
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629432
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629434
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629436
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629438
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629440
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629442
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629444
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629446
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629448
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629450
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629452
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629454
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629456
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629458
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629460
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629462
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629464
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629466
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629468
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629470
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629472
Principal investigator 1 Exelixis Inc. $275.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629474
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629476
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629478
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629480
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629482
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629484
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629486
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629488
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629490
Principal investigator 1 Exelixis Inc. $275.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629492
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629500
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629504
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629506
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629508
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629510
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629512
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629514
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629516
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629518
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629520
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629522
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629524
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629526
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629528
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629530
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629534
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629536
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629538
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629540
Principal investigator 1 Exelixis Inc. $142.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629542
Principal investigator 1 Exelixis Inc. $500.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629544
Principal investigator 1 Exelixis Inc. $365.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629546
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629548
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629550
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629552
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629554
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629556
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629558
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629560
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629562
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629564
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629566
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629568
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629570
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629572
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629574
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629576
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629578
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629580
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629582
Principal investigator 1 Exelixis Inc. $150.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629584
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629586
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629588
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629592
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629594
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629596
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629598
Principal investigator 1 Exelixis Inc. $75.00 04/16/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138629600
Principal investigator 1 ABBVIE INC. $1,668.60 04/02/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100710524
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $8,305.00 03/15/2024 Non-covered Recipient Entity
New Experimental Therapeutics of Austin - NEXT Oncology
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1133406128
Principal investigator 1 Exelixis Inc. $482.63 03/11/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628866
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,500.00 03/08/2024 Non-covered Recipient Entity
New Experimental Therapeutics of Austin - NEXT Oncology
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1133406126
Principal investigator 1 Exelixis Inc. $189.05 03/04/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628856
Principal investigator 1 Exelixis Inc. $775.00 03/04/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628860
Principal investigator 1 Exelixis Inc. $1,315.00 03/04/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628876
Principal investigator 1 Exelixis Inc. $485.00 03/04/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628878
Principal investigator 1 Exelixis Inc. $1,315.00 03/04/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628882
Principal investigator 1 Exelixis Inc. $116.68 03/04/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628884
Principal investigator 1 Exelixis Inc. $775.00 03/04/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628900
Principal investigator 1 ABBVIE INC. $485.00 02/28/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100705144
Principal investigator 1 ABBVIE INC. $1,315.00 02/28/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100705146
Principal investigator 1 ABBVIE INC. $1,700.00 02/28/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100705148
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,300.00 02/28/2024 Non-covered Recipient Entity
New Experimental Therapeutics of Austin - NEXT Oncology
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1133406122
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $525.00 02/28/2024 Non-covered Recipient Entity
New Experimental Therapeutics of Austin - NEXT Oncology
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1133406124
Principal investigator 1 Deciphera Pharmaceuticals Inc. $13,108.77 02/21/2024 Non-covered Recipient Entity
NEXT ONCOLOGY - AUSTIN
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1146135007
Principal investigator 1 Deciphera Pharmaceuticals Inc. $27,390.00 02/09/2024 Non-covered Recipient Entity
NEXT ONCOLOGY - AUSTIN
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1146134965
Principal investigator 1 ABBVIE INC. $3,600.00 01/31/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100701200
Principal investigator 1 ABBVIE INC. $1,601.10 01/29/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100701144
Principal investigator 1 Deciphera Pharmaceuticals Inc. $13,108.77 01/24/2024 Non-covered Recipient Entity
NEXT ONCOLOGY - AUSTIN
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1146134859
Principal investigator 1 ABBVIE INC. $4,313.25 01/17/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100700413
Principal investigator 1 ABBVIE INC. $2,214.00 01/17/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100700415
Principal investigator 1 ABBVIE INC. $5,134.05 01/17/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100700417
Principal investigator 1 ABBVIE INC. $1,601.10 01/17/2024 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100700419
Principal investigator 1 Deciphera Pharmaceuticals Inc. $13,108.77 01/04/2024 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1146134677